The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. by Bradley, Clare et al.
BioMed CentralHealth and Quality of Life 
ssOpen AcceResearch
The Diabetes Treatment Satisfaction Questionnaire change version 
(DTSQc) evaluated in insulin glargine trials shows greater 
responsiveness to improvements than the original DTSQ
Clare Bradley*1, Rosalind Plowright1, John Stewart2, John Valentine1 and 
Elke Witthaus3
Address: 1Health Psychology Research, Dept of Psychology, Royal Holloway, University of London, UK, 2Dept of Biostatistics, sanofi-aventis 
Pharma, Laval, Quebec, Canada and 3Health Outcomes Research, Accovion GmbH, Eschborn, Germany
Email: Clare Bradley* - c.bradley@rhul.ac.uk; Rosalind Plowright - r.plowright@rhul.ac.uk; John Stewart - john.stewart@sanofi-aventis.com; 
John Valentine - jd.valentine@virgin.net; Elke Witthaus - elke.witthaus@accovion.com
* Corresponding author    
Abstract
Background: The results of using status measures to identify any changes in treatment satisfaction
strongly suggest a need for specific change instruments designed to overcome the ceiling effects
frequently observed at baseline. Status measures may leave little room to show improvement in
situations where baseline ceiling effects are observed. A change version of the DTSQ (DTSQc) is
compared here with the original status (now called DTSQs) version to test the instruments'
comparative ability to demonstrate change.
Methods: Two multinational, openlabel, randomised-controlled trials (one for patients with type
1 diabetes, the other for type 2) compared new, longer-acting insulin glargine with standard NPH
basal insulin. The DTSQs was completed at baseline and the DTSQs and DTSQc at final visit by
351 English- and German-speaking patients. DTSQc scores were compared with change from
baseline for the DTSQs, using 3-way analysis of variance, to examine Questionnaire, Treatment and
Ceiling effects (i.e. baseline scores at/near ceiling).
Results and discussion: Significant Questionnaire effects and a Questionnaire × Ceiling
interaction (p < 0.001) in both trial datasets showed that the DTSQc detected more improvement
in Treatment Satisfaction than the DTSQs, especially when patients had DTSQs scores at/near
ceiling at baseline. Additionally, significant Treatment effects favouring insulin glargine (p < 0.001)
and a Treatment × Questionnaire interaction (p < 0.019), with the DTSQc showing more benefits,
were found in the type 1 trial. Results for Perceived Hyper- and Hypoglycaemia also demonstrated
important differences between the questionnaires in the detection of treatment effects. Tests of
effect sizes showed these differences in response to change to be significantly in favour of the
DTSQc.
Conclusion: The DTSQc, used in conjunction with the DTSQs, overcomes the problem of ceiling
effects encountered when only the status measure is used and provides a means for new
treatments to show greater value than is possible with the DTSQs alone.
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Patients are inclined to make the best of their current
treatment and only become aware of its drawbacks when
they can compare it with something better [1]. A fre-
quently observed feature in trials of new treatments for
diabetes is therefore a relatively high level of patient satis-
faction with pre-trial treatment [2-5]. This is true not only
of diabetes trials. High levels of patient satisfaction are
widely found across different conditions. Patient satisfac-
tion surveys produce little variation and most respondents
express positive satisfaction [6]. Researchers evaluating
diabetes treatment interventions have commonly used the
Diabetes Treatment Satisfaction Questionnaire in its orig-
inal 'status' form (for example. [2-5]) (e.g. How satisfied
are you with your current treatment? Response options: very
satisfied to very dissatisfied). This leaves those respondents
who were already very satisfied beforehand with little or
no room to show improved satisfaction later in the trial
[7,8]. The problem is not unique to the DTSQs. Skewed
satisfaction scores reflect a real phenomenon and not a
failure of the scale, so changing the scale is not a good
solution. Although the skew could be dealt with statisti-
cally and the scale adjusted to fit the majority scoring pat-
tern (i.e. skewed in favour of positive satisfaction), such
an adjustment would reduce the validity of the scale for
those patients who are sometimes very dissatisfied [8]. A
change version of the DTSQ (DTSQc) was therefore
designed to overcome such ceiling effects found with the
Status version (DTSQs) [8].
Aventis (previously Hoechst Marion Roussel and now
sanofi aventis) has conducted multinational Phase III tri-
als comparing insulin glargine, a new longer-acting insu-
lin providing constant release of insulin without a
pronounced peak, with widely used NPH insulin [9-11].
Measures of psychological outcomes included the DTSQs
and the new DTSQc in two languages, English and Ger-
man.
It was hypothesised that the DTSQc would be more
responsive to treatment change particularly when
respondents had scored at or near ceiling on the DTSQs at
baseline. It was also expected that treatment satisfaction
would be greater with insulin glargine given its longer
action and constant release of insulin without a pro-
nounced peak, achieved with only one daily injection
compared with NPH insulin which even with two injec-
tions daily provides variable release of insulin.
Methods
Questionnaire
The DTSQc was developed from the widely used and rec-
ommended DTSQs [e.g. [5,12,13]], available in a wide
range of languages [e.g. [3,14,15]], the development of
which is reported in detail elsewhere [5,16]. Both forms of
the DTSQ are suitable for use by people with type 1 or
type 2 diabetes. Like the DTSQs, the DTSQc contains eight
items scored on 7-point scales. Six items (Qs.1 and 4–8)
measure Treatment Satisfaction (dealing with: satisfaction
with current treatment; convenience of the treatment;
flexibility; satisfaction with own understanding of their
diabetes; how likely to recommend their present treat-
ment; and how satisfied to continue with their present
treatment). These are summed to produce a total Treat-
ment Satisfaction score. Questions 2/3, concerning Per-
ceived Frequency of Hyperglycaemia ('Perceived
Hyperglycaemia')/Perceived Frequency of Hypoglycaemia
('Perceived Hypoglycaemia') respectively, are treated sep-
arately from the satisfaction items and from each other
[5,16]. On these two items, low scores represent good per-
ceived blood glucose control. The most common factor
structures seen for the DTSQs show all the Satisfaction
items loading together on factor 1 (this is the only impor-
tant aspect of the questionnaire structure indicating a
coherent scale measuring treatment satisfaction), with the
Perceived Hyper- and Hypoglycaemia items (items 2 and
3) loading together on factor 2 or separately on factors 1
and 2 or on 2 and 3. It was predicted that the same pattern
would be seen with the DTSQc with all six treatment sat-
isfaction items loading on factor 1. The wording of the
items themselves is the same for both the status and
change versions, the small exception being part of the
wording of item 7 (recommending the treatment). The
important differences lie in the wording of the response
options and instructions, which, in the DTSQc, direct the
respondent to compare their experience of the current
treatment with their experience of treatment before the
study began. DTSQs scores range from, for example, 6 =
very satisfied to 0 = very dissatisfied and DTSQc scores from
+3 = much more satisfied now to -3 = much less satisfied now,
with 0 (midpoint), representing no change.
German was the first language version of the DTSQc to be
evaluated (on an Austrian population) [17]. The original
English is evaluated here (UK and S.Africa) for the first
time and the German is used here for the first time in Ger-
many and Switzerland as well as Austria.
The Status version was completed by patients at both
baseline and endpoint. The Change version was com-
pleted only at endpoint. At endpoint patients completed
the Status measure before completing the Change version.
Patients
The subset of patients from the first two European trials to
provide DTSQc data included: 198 patients with type 1
diabetes and 153 patients with type 2 diabetes. The two
datasets were analysed separately. Of the total 351
patients in the two studies, 89 were English-speaking
(NBritish = 27; NS. African = 62) and 262 were German-speak-Page 2 of 12
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inclusion criterion was level of glycosylated haemoglobin
(GHb) at Visit 1: ≤ 12.0% for patients with type 1; 7.5-
12.0% for patients with type 2 diabetes. Patients were ran-
domised to insulin glargine or NPH insulin. During the
treatment phase (type 1 study = 28 weeks; type 2 study =
52 weeks), insulin glargine was administered by subcuta-
neous injection once daily at bedtime; NPH human insu-
lin was administered by subcutaneous injection once or
more than once daily (depending on the previous regi-
men) in the type 1 study, and once only at bedtime in the
type 2 study (in the type 2 study 73.6% of patients overall
had not used insulin prior to study entry; in the analyses
here the proportion was 75.2% with no prior experience
of insulin). In the type 1 study, in addition to insulin
glargine or NPH, regular human insulin was administered
before each meal. Table 1 shows the whole sample, bro-
ken down by their main demographic and clinical charac-
teristics.
Data analysis
Prior to performing psychometric analyses, the combina-
bility of the subgroups (defined by country and type of
diabetes) was tested by a method described elsewhere
[18], which confirmed the acceptability of combining the
samples.
Psychometric analysis
Psychometric analysis was carried out to check the validity
and reliability of the English- and German-speaking ver-
sions (separately for language, pooled for type of diabe-
tes), using factor analysis with principal components as
the extraction method with Varimax rotation. The crite-
rion for the number of factors extracted in the unforced
analysis was the number of principal components with
eigenvalues greater than 1.0. A three-factor structure was
subsequently forced. Reliability analysis (including Cron-
bach's alpha) was conducted on the six items intended to
form the Treatment Satisfaction scale.
Alignment of scores for comparison purposes
For the comparative responsiveness analyses between the
DTSQs and DTSQc, difference scores for the DTSQs were
calculated (endpoint, minus baseline scores). Thus,
increases in treatment satisfaction produced positive
scores and decreases negative scores. The two scales being
compared have different widths. DTSQc scores range
potentially from -18 to +18, while DTSQs difference
scores range potentially from -36 to +36. Dividing the
DTSQs difference scores by 2 provided the variable
labelled DTSQsDiff, which was equivalent in range to the
DTSQc scores. For Perceived Hyperglycaemia and
Hypoglycaemia, positive scores indicate an increase in
Perceived Hyperglycaemia or Hypoglycaemia and hence
deterioration in these outcomes. Endpoint-minus-base-
line DTSQs scores for these 2 items were also divided by 2
to produce DTSQsDiff scores and allow direct comparison
with DTSQc scores for Perceived Hyperglycaemia and
Hypoglycaemia.
Only respondents with Treatment Satisfaction scores on
both DTSQsDiff and DTSQc were included; likewise with
the two items concerning perceived blood glucose con-
trol.
Categorising scores as 'at ceiling/not at ceiling' or 'at floor/not at floor'
The terms 'at ceiling' (for Satisfaction) and 'at floor' (for
Perceived Hyperglycaemia and Hypoglycaemia) would
usually be defined as being just the maximum and mini-
mum scores respectively. However, since those people
with scores close to, but not at maximum/minimum
would have very little room to show increases or
decreases, the definitions of At Ceiling and At Floor have
been widened here. At Ceiling Treatment Satisfaction
scores are defined here as ≥ 30 (maximum = 36) and At
Floor scores (Perceived Hyperglycaemia and Hypoglycae-
mia) as ≤ 1 (minimum = 0). Other scores are referred to as
Not at Ceiling and Not at Floor. These categorisations were
made on raw DTSQs baseline scores, prior to rescaling as
described above.
ANOVA: comparing treatment differences shown by the two 
questionnaires in subgroups scoring at ceiling (floor)/not at ceiling 
(floor)
Analysis of responsiveness to change was carried out on
the three dependent variables, change in Treatment Satis-
faction, change in Perceived Hyperglycaemia, and change
in Perceived Hypoglycaemia, using three-way analysis of
variance (ANOVA) with Treatment (2 levels), Question-
naire (2 levels) and Ceiling effect (2 levels). Distributions
were skewed for Treatment Satisfaction scores and Per-
ceived Hypoglycaemia, so the ANOVA was carried out on
raw scores and additionally on the ranks of the scores.
Treatment Satisfaction scores across both questionnaires
were ranked separately for each study. To lend greater
Table 1: Demographic and clinical characteristics of the whole 
sample
Characteristics Type 1 Type 2
N 
(missing)
Mean 
(SD)
N 
(missing)
Mean 
(SD)
Age 198 (0) 39 (12) 153 (0) 59 (10)
Sex: Male/Female 108/90 (0) - 82/71 (0) -
Previously on 
insulin: Yes/No
198/0 (0) - 38/115 (0) -
GHb at baseline 197 (1) 7.66 (1.13) 149 (4) 8.93 (1.12)Page 3 of 12
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the supporting table of results are based on raw scores. In
the very few (three) instances where the ranked results dif-
fer noticeably from the raw results, these are indicated on
the table.
Effect sizes: comparing the two questionnaires in subgroups scoring 
at ceiling (floor)/not at ceiling (floor)
To explore further the sensitivity to change of the ques-
tionnaires an analysis of effect sizes was conducted in
addition to the analysis of variance. The effects of treat-
ment for the two questionnaires were compared regard-
less of whether the treatment was NPH or glargine. Effect
sizes for the two treatment satisfaction scales (DTSQsDiff
and DTSQc) were compared separately for the At Ceiling
and Not at Ceiling groups, by testing the mean rated
change (DTSQc) or DTSQsDiff scores, by t-tests against a
hypothetical mean of zero and converting the resulting t-
values to values of r, as a measure of effect-size. The signif-
icance of the difference between the r values resulting
from the DTSQc and DTSQsDiff measures was then tested
by the use of Fisher's z transformation of r [19].
Results
Psychometric analyses
An unforced two-factor structure of the DTSQc was seen in
both languages (see Table 2). All Treatment Satisfaction
items loaded highly on Factor 1 (English range = 0.81 to
0.94; German range = 0.71 to 0.90), with the two per-
ceived blood glucose control items loading highly on Fac-
tor 2 (English range = 0.73 to 0.81; German range = 0.74
to 0.86). When forced into three factors, the two perceived
blood glucose control items separated and loaded even
more highly on Factor 2 (Perceived Hyperglycaemia) and
Factor 3 (Perceived Hypoglycaemia), as shown in Tables 3
and 4. Cronbach's alpha coefficient for the Treatment Sat-
isfaction scale (i.e. excluding the two perceived blood glu-
cose control items) was 0.92 for the English and 0.94 for
the German.
Distributions of scores
As anticipated, distribution of the raw baseline DTSQs
scores was skewed for Treatment Satisfaction and Per-
ceived Hypoglycaemia [5]; while Perceived Hyperglycae-
mia scores were normally distributed. Those patients
recording baseline Treatment Satisfaction scores At Ceiling
accounted for nearly half (49%) of those in the type 1
trial, and almost two-thirds (62%) in the type 2 trial. For
Perceived Hypoglycaemia, those scoring At Floor at base-
line accounted for 48% (type 1) and 79% (type 2). How-
ever, only 18% and 20% of patients (for type 1 and type 2
respectively) recorded baseline Perceived Hyperglycaemia
scores At Floor.
ANOVA: comparing treatment differences shown by the 
two questionnaires in subgroups scoring at ceiling (floor)/
not at ceiling (floor)
Of the six sets of results (type 1 and type 2) for each of the
three principal variables, change in Treatment Satisfaction
(Tables 5 and 6), change in Perceived Hyperglycaemia
(Tables 7 and 8) and change in Perceived Hypoglycaemia
(Tables 9 and 10), the most relevant for comparison of the
DTSQc with the DTSQs were those with skewed baseline
distributions (Satisfaction and Perceived Hypoglycaemia)
and attention is therefore focused primarily on these. Fig-
ures 1 and 2 provide two examples of the results, one for
Treatment Satisfaction and one for Perceived Hypoglycae-
mia (both from the type 1 trial). For clarity of reading, all
the ANOVA results, with both main effects and interac-
tions, are presented in Tables 5, 7 and 9, and their related
tables of means are given in Tables 6, 8 and 10 respec-
tively. The text is restricted to the interpretation of these
results.
Change in treatment satisfaction
Type 1 trial
Treatment Satisfaction increased overall in both the insu-
lin glargine and NPH treatment groups, but with a signif-
icantly greater increase in the insulin glargine group.
Figure 1 shows the DTSQc was markedly more responsive
than the DTSQsDiff across all subgroups, including the
Table 2: English and German unforced (two-factor) analyses
Item English (n = 83) German (n = 250)
Component 1 (Satisfaction) Component 2 (PercBGC) Component 1 (Satisfaction) Component 2 (PercBGC)
1 Satisfied 0.817 -0.075 0.878 -0.215
2 Hyperglycaemia -0.029 0.807 -0.272 0.735
3 Hypoglycaemia -0.094 0.734 -0.103 0.857
4 Convenient 0.943 -0.149 0.868 -0.152
5 Flexible 0.830 0.076 0.896 -0.209
6 Understanding 0.808 -0.053 0.705 -0.249
7 Recommend 0.812 -0.139 0.865 -0.190
8 Continue 0.915 -0.099 0.899 -0.159Page 4 of 12
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interaction indicates that, among those patients with
baseline scores At Ceiling, the DTSQc showed increases in
Treatment Satisfaction, while the DTSQsDiff showed
small mean decreases. Using the DTSQc, the At Ceiling
group showed a greater increase in Satisfaction than the
Not at Ceiling group. However, it was expected that the Not
at Ceiling group would be better able to show an increase
in Treatment Satisfaction than the At Ceiling group, if they
were using the DTSQsDiff, and this was indeed the case.
As Figure 1 also shows, no matter how patients scored at
baseline, the insulin glargine group showed greater
improvement in Treatment Satisfaction than the NPH
group when scoring with the DTSQc than when scoring
with the DTSQsDiff (see Table 5, treatment × question-
naire interaction).
Type 2 trial
Unlike the type 1 study, no main effect of Treatment was
seen for patients with type 2 diabetes. However, as in the
type 1 trial, the DTSQc detected greater increases in satis-
faction than the DTSQsDiff, and the interaction with Ceil-
ing effects shows that once again the difference between
status and change versions of the DTSQ was especially
marked in the At Ceiling subgroup (see Table 6).
Change in perceived hypoglycaemia
Type 1 trial
Patients with type 1 diabetes showed an overall reduction
in Perceived Hypoglycaemia, with those in the insulin
glargine group showing a significantly greater reduction.
There was a main effect of Questionnaire, with the DTSQc
showing greater effects (see Figure 2). Reductions in Per-
ceived Hypoglycaemia were observed in all the Question-
naire × Floor/Not at Floor subgroups except one: when
those At Floor were scoring on the DTSQsDiff, they
showed a slight increase. The reductions in the other sub-
groups were seen most clearly among those At Floor using
the DTSQc (see Table 7, the significant Floor × Question-
naire interaction). The DTSQc also showed a greater
responsiveness than the DTSQsDiff to Treatment differ-
ences (Questionnaire × Treatment interaction), although
this did not quite reach significance on the ranked (two-
tailed) test (p = 0.051).
Type 2 trial
Treatment effects on Perceived Hypoglycaemia observed
in the type 2 participants only became significant in the
interaction with Questionnaire and Floor effect. Regard-
less of Treatment, there were greater reductions overall in
Perceived Hypoglycaemia in those Not at Floor to start
with (main effect of floor). The DTSQc showed more
improvements in Perceived Hypoglycaemia than the
DTSQsDiff (main effect of Questionnaire), principally
because the change version continued to detect improve-
ments where there were Floor effects, whereas the status
version did not (see the highly significant Floor × Ques-
tionnaire interaction in Table 7). When using the status
measure with people At Floor, an increase in Perceived
Hypoglycaemia is apparent, while the change version
shows reductions (i.e. improvements) in Perceived
Hypoglycaemia for both insulin glargine and NPH.
Change in perceived hyperglycaemia
Type 1 trial
Only 18% of people fell into the At Floor subgroup on this
variable. However, the principal features observed with
the Treatment Satisfaction results, such as the main effect
of Questionnaire and the interaction between Question-
naire and Floor effect, were observed once again, with the
Change version showing greater improvements (reduc-
tions) in Perceived Hyperglycaemia than the Status ver-
sion, particularly in those already reporting little
hyperglycaemia at baseline.
Type 2 trial
Only 20% of people fell into the At Floor subgroup. The
DTSQc showed significantly greater improvements in Per-
ceived Hyperglycaemia than the DTSQs (Questionnaire
effect) in those people reporting little hyperglycaemia at
baseline (interaction with Floor effect). However, as in the
Type 1 trial, in the people At Floor, Perceived Hyperglycae-
mia was seen to increase in frequency when people were
scoring on the DTSQsDiff.
Table 4: Forced 3-factor analysis of German data (N = 250)
Item Component 1 
Satisfaction
Component 2 
Perceived 
Hyperglycaemia
Component 3 
Perceived 
Hypoglycaemia
1 Satisfied 0.858 -0.320 -0.019
2 Hyperglycaemia -0.213 0.940 0.192
3 Hypoglycaemia -0.150 0.175 0.955
4 Convenient 0.883 -0.009 -0.185
5 Flexible 0.906 -0.088 -0.195
6 Understanding 0.717 -0.093 -0.242
7 Recommend 0.854 -0.240 -0.050
8 Continue 0.884 -0.247 -0.005
Table 3: Forced 3-factor analysis of English data (N = 83)
Item Component 1 
Satisfaction
Component 2 
Perceived 
Hyperglycaemia
Component 3 
Perceived 
Hypoglycaemia
1 Satisfied 0.812 -0.095 -0.221
2 Hyperglycaemia -0.043 0.968 0.120
3 Hypoglycaemia -0.080 0.120 0.976
4 Convenient 0.944 -0.111 -0.099
5 Flexible 0.828 0.124 -0.025
6 Understanding 0.808 -0.025 -0.051
7 Recommend 0.818 -0.266 0.095
8 Continue 0.916 -0.098 -0.037Page 5 of 12
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differences of the two questionnaires in subgroups scoring 
at ceiling (floor)/not at ceiling (floor)
In the type 1 study, for the Not at Ceiling group, the t-value
for the DTSQsDiff Treatment Satisfaction measure was
t(94) = 3.30 and for the DTSQc was t(97) = 11.97, which
translate into r values of 0.32 and 0.77, respectively. The z
score for the difference between the Fisher transformation
of these values is z = 4.73, indicating a markedly larger
effect size for the DTSQc than for the DTSQsDiff (see
Table 11). For the At Ceiling group the corresponding val-
ues were t(91) = 2.44, r = 0.25 for the DTSQsDiff and
t(95) = 15.64, r(change) = 0.85 for the DTSQc, and the z
score of the difference between these r values = 10.15, an
even more marked difference than for the Not at Ceiling
group. Each of these t-tests is for independent groups.
Since the two measures (DTSQsDiff and DTSQc) are not
independent, these two t-tests are not independent of
each other. Thus, for example, in the type 1 study for the
treatment satisfaction variable in the glargine group
Spearman's rho is 0.36, n = 99, p < 0.001 for the correla-
tion between DTSQsDiff and DTSQc. Given these positive
correlations it is more difficult to show differences
between the two questionnaires. However, as the effect
sizes based on these ts differ significantly despite the pos-
itive correlations, the stated results are conservative. For
both groups, At Ceiling (Floor)/Not at Ceiling (Floor), there-
fore, the change measure is significantly more responsive
than the DTSQsDiff measure. Furthermore, a simple test
of the difference between these two z scores (4.73 and
10.15), using a standard error of the square root of 2, gives
a final z value of 3.83, indicating that the superior respon-
siveness of the change measure is significantly greater in
the At Ceiling group than in the Not at Ceiling group.
Equivalent figures for the Perceived Hypo/Hyperglycae-
mia variables and for the type 2 trial follow a similarly sig-
nificant pattern (see Table 11).
Using non-parametric tests on the same Type 1 treatment
satisfaction data, a similarly high and significant final z
value of 3.17 was obtained. Similar patterns of results,
showing that the superiority of the change measure was
Table 6: "Treatment Satisfaction" – Descriptive Statistics
Change Questionnaire Status Questionnaire
glargine treatment NPH treatment glargine treatment NPH treatment
At Ceiling Not Ceiling At Ceiling Not Ceiling At Ceiling Not Ceiling At Ceiling Not Ceiling
Type 1 Study
Mean change 12.709 10.744 9.278 6.196 -0.427 2.163 -1.014 0.353
SD 7.023 4.885 6.679 7.707 2.629 3.078 2.425 3.235
N 55 43 36 51 55 43 36 51
Type 2 Study
Mean change 16.273 14.115 15.806 14.565 4.269 0.432 2.783 0.236
SD 3.330 3.963 3.345 3.776 1.655 3.465 1.290 3.599
N 44 26 36 23 44 26 36 23
Table 5: "Treatment Satisfaction" – Summary of Results of 3-way ANOVA (on Raw Data)
Main Effects & Interactions Type 1 Study Type 2 Study
F df1, df2 p F df1, df2 p
Treatment 15.71 1,181 <0.0001 0.85 1,125 0.360
Ceiling 0.17 1,181 0.678 2.61 1,125 0.109*
Questionnaire 538.04 1,181 <0.0001 1833.88 1,125 <0.0001
Treatment × Ceiling 0.80 1,181 0.373 0.04 1,125 0.840
Treatment × Questionnaire 11.70 1,181 0.001 1.81 1,125 0.181
Ceiling × Questionnaire 30.44 1,181 <0.0001 62.37 1,125 <0.0001
Treatment × Ceiling × Questionnaire 0.00 1,181 0.948 3.18 1,125 0.077
* Ranked results were significant (p = 0.004)Page 6 of 12
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ing at baseline, were obtained for treatment satisfaction in
the Type 2 study. (Since the non-parametric results are
similarly significant, only the parametric results are pre-
sented in Table 11).
The pattern of results for the perceived frequency of hyper-
and hypoglycaemia also showed markedly greater respon-
siveness of the DTSQc measure (compared with the
DTSQsDiff) in the At Floor groups. Although Table 11 sug-
gests that the DTSQsDiff may be more responsive to
(either) treatment than the DTSQc in the Not at Floor
group, the advantage is small compared with the advan-
tage of the DTSQc in the At Floor group and inspection of
Figure 2 reveals that the DTSQc showed bigger differences
between the two treatments studied, glargine and NPH. As
the non-parametric tests again mirrored the parametric
tests, only the latter are presented.
Discussion
The expected structure and reliability of the DTSQc is con-
firmed in both languages. Howorka and colleagues [17]
have already found the German DTSQc to perform well
with Austrian patients with type 1 diabetes comparing
meal-related insulins. The insulin glargine studies here
add to that work, providing validation of the English ver-
sion (for UK and S.Africa), confirming the validity of the
German version for Austria and now Germany for the first
time, for patients with both type 1 and type 2 diabetes.
Additionally, the impact of ceiling and floor effects is
investigated here in detail.
Given the nature of insulin glargine, with its longer action
and constant release of insulin without a pronounced
peak, achieved with only one daily injection of basal insu-
lin, it was expected that treatment satisfaction would be
greater in the insulin glargine group than the NPH group.
Once-daily insulin glargine has been shown to be associ-
ated with at least similar glycaemic control with fewer
hypoglycaemic episodes than NPH insulin [9,20,21]. The
Table 8: "Perceived Hypoglycaemia" – Descriptive Statistics
Change Questionnaire Status Questionnaire
glargine treatment NPH treatment glargine treatment NPH treatment
At Floor Not Floor At Floor Not Floor At Floor Not Floor At Floor Not Floor
Type 1 Study
Mean change -0.755 -0.980 -0.581 -0.041 0.429 -0.578 0.360 -0.337
SD 1.422 1.378 1.277 1.471 0.520 0.586 0.630 0.860
N 49 51 43 49 49 51 43 49
Type 2 Study
Mean change -0.842 -1.350 -1.393 -0.300 0.395 -0.950 0.295 -1.200
SD 1.645 1.599 1.510 1.947 0.854 0.742 0.666 0.823
N 57 20 56 10 57 20 56 10
Table 7: "Perceived Hypoglycaemia" – Summary of Results of 3-way ANOVA (on Raw Data)
Main Effects & Interactions Type 1 Study Type 2 Study
F df1, df2 p F df1, df2 p
Treatment 6.86 1,188 0.010 0.03 1,139 0.957
Floor 8.00 1,188 0.005 7.45 1,139 0.007
Questionnaire 32.63 1,188 <0.0001 11.88 1,139 0.001
Treatment × Floor 4.80 1,188 0.030 3.08 1,139 0.081
Treatment × Questionnaire 5.79 1,188 0.017† 1.46 1,139 0.229
Floor × Questionnaire 65.24 1,188 <0.0001 23.69 1,139 <0.0001
Treatment × Floor × Questionnaire 1.36 1,188 0.245 6.19 1,139 0.014
† ranked results = NS (0.051)Page 7 of 12
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ment Satisfaction and Perceived Hypoglycaemia from
using insulin glargine among patients with type 1 diabe-
tes. Benefits of insulin glargine are also seen among
patients with type 2 diabetes, although these only show
up in the three-way interaction of treatment × question-
naire × floor effect for Perceived Hypoglycaemia and not
in the main effects of Treatment. Thus benefits attributa-
ble to glargine, which would not be revealed by the
DTSQs alone, are revealed by the DTSQc when used with
people scoring at or near floor at baseline. Treatment
effects on the DTSQs results in the datasets from other
countries included in these Phase III trials are reported
elsewhere [10,11].
It was predicted that the DTSQc would prove to be more
responsive to change than the DTSQs and the present
results confirm this. The differences expected were princi-
pally between the two Questionnaires and their interac-
tion with Ceiling/Floor effects and these were found to be
highly significant for all three variables (measuring
changes in Treatment Satisfaction, Perceived Hyperglycae-
mia and Hypoglycaemia) across both trials (type 1 and 2).
The DTSQc performed as intended, showing significantly
enhanced responsiveness to improvements in Treatment
Satisfaction, particularly among patients At Ceiling at
baseline, as well as greater responsiveness to improve-
ments in perceived blood glucose control. In those
patients with baseline scores At Ceiling/Floor, the DTSQc
consistently showed improvements with glargine across
all variables and both patient populations (i.e. type 1 and
2). In contrast, among those At Ceiling/Floor, the DTSQs-
Diff showed either a much smaller improvement, or more
often in the At Ceiling/Floor groups, a slight deterioration.
In the At Ceiling/Floor groups, those few patients reporting
decreased satisfaction or increased hypo- or hyperglycae-
mia have a disproportionate influence on mean scores of
the DTSQsDiff, as patients wishing to register improve-
ments had much less scope for doing so than those wish-
ing to register a deterioration. The new Change measure
allowed patients equal opportunity for indicating
improvement and deterioration. As expected, which ques-
Table 10: "Perceived Hyperglycaemia" – Descriptive Statistics
Change Questionnaire Status Questionnaire
glargine treatment NPH treatment glargine treatment NPH treatment
At Floor Not Floor At Floor Not Floor At Floor Not Floor At Floor Not Floor
Type 1 Study
Mean change -1.208 -0.767 -1.600 0.171 0.313 -0.459 0.350 -0.311
SD 1.414 1.603 1.430 1.530 0.673 0.798 0.669 0.706
N 24 73 10 82 24 73 10 82
Type 2 Study
Mean change -0.933 -0.644 -1.462 -0.185 0.600 -1.025 0.385 -0.972
SD 1.831 2.057 2.184 2.066 0.967 1.112 0.961 0.949
N 15 59 13 54 15 59 13 54
Table 9: "Perceived Hyperglycaemia" – Summary of Results of 3-way ANOVA (on Raw Data)
Main Effects & Interactions Type 1 Study Type 2 Study
F df1, df2 p F df1, df2 p
Treatment 0.89 1,185 0.346 0.04 1,137 0.841
Floor 1.01 1,185 0.315 1.51 1,137 0.221
Questionnaire 28.72 1,185 <0.0001 8.88 1,137 0.003
Treatment × Floor 3.46 1,185 0.064 1.19 1,137 0.278
Treatment × Questionnaire 0.34 1,185 0.558 0.02 1,137 0.901
Floor × Questionnaire 35.08 1,185 <0.0001 37.55 1,137 <0.0001
Treatment × Floor × Questionnaire 3.93 1,185 0.049‡ 0.94 1,137 0.335
‡ ranked results = NS (0.067)Page 8 of 12
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group, since patients still had room to show increases in
Satisfaction when using the DTSQs, and did so.
The breakdown of the data into subgroups of participants
At Ceiling/Floor and those Not at Ceiling/Floor is necessarily
an imperfect division, based as it is on splitting scores
along a continuum. Nevertheless, the division has served
in these analyses to highlight clearly the limitations that
can be associated with measuring change in satisfaction
using a status measure, where so many people, who have
already scored at or near ceiling at baseline, wish to regis-
ter marked improvements at endpoint; likewise for those
recording optimal baseline scores at or near floor for Per-
ceived Frequency of Hyperglycaemia or Hypoglycaemia.
Thus the division has made it possible to have a clearer
picture of the benefits of using an explicit change measure
at endpoint.
It is important to note that, although the benefits of the
change measure are most apparent in the Treatment Satis-
faction scores from patients scoring At Ceiling at baseline,
the DTSQc is also more responsive to change than the
DTSQsDiff in patients who were Not at Ceiling to start
with. Figure 1, for example shows that mean improve-
ments in satisfaction (using the Change measure) of
10.74 were shown in the Not at Ceiling insulin glargine
group. Patients would have to score 25 or less (out of a
possible 36) on the DTSQs at baseline to be able to regis-
ter such an improvement in DTSQs scores and few do
score this low to start with. Thus, even in the Not at Ceiling
subgroups, defined here as scoring <30 on the DTSQs at
baseline, ceiling is reached by many who wish to register
marked improvements in satisfaction. The DTSQc shows
enhanced responsiveness to change in these patients too.
In the case of the two perceived blood glucose control
items, the DTSQc is unequivocally more responsive to
improvements in hypoglycaemia for those in the At Floor
group. For those Not at Floor, the DTSQsDiff measure
shows greater responsiveness to change as indicated by
the D values shown in Table 11. However the advantages
of the DTSQc measure in the At Floor group far outweigh
the advantages of the DTSQsDiff measure in the Not at
Floor group. Furthermore the effect size measures reported
in Table 11 do not refer to differences between the insulin
treatments but rather refer to change associated with
either treatment. For indications of responsiveness to dif-
ferences between glargine and NPH we can refer to Figure
2 which suggests that the DTSQc is more responsive to
change associated with insulin glargine (the newly intro-
duced treatment in this Type 1 trial) than is the DTSQsDiff
measure particularly in the Not at Floor group. As expected
in this Type 1 trial illustrated in Figure 2, there were less
marked changes from baseline for the NPH treatment
group, most of whom would have used NPH insulin prior
to baseline as well as during the study. Therefore, it
remains the case that for the Treatment Satisfaction varia-
ble and for the Perceived Frequency of Hyper- and
Hypoglycaemia variables, the DTSQc is the measure of
choice, whether or not patients score at/near ceiling at
baseline.
Other authors have compared prospective (status) and
retrospective (change) measures of health status and
symptoms and, as in the present dataset, found more pro-
nounced changes with the retrospective change measure
following treatment, than with the status measure used
pre- and post- treatment [22]. Aseltine and colleagues sug-
gested that status measures may not be an error-free
method of measuring change, because patients' standards,
or the criteria they use to determine their ratings, may
change following treatment as their frame of reference
may change, so that apparently identical ratings are not, in
fact, comparable. Aseltine et al did not consider the role of
Differential responsiveness of the DTSQ change and DTSQ status: perceived frequency f ypoglycaemia (Type 1 trial)Fig  2
Differential responsiveness of the DTSQ change and DTSQ 
status: perceived frequency of hypoglycaemia (Type 1 trial).
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measures, although the data they presented suggest that
ceiling effects with the status version of the health status
measure they used may have increased the difference
between the status and change measures, while the symp-
tom measure used appeared little affected by ceiling or
floor effects and also gave rise to fewer discrepancies
between status and change measures. Where the capacity
for change in status scores is limited by ceiling or floor
effects, a retrospective change measure with no such limi-
tations will provide a more valid measure of the benefits
of treatment.
Another potential concern with a retrospective measure of
change is that it might reflect a socially desirable tendency
to report improved satisfaction whatever the treatment
rather than genuine change. The evidence is that the
DTSQc does not. Howorka et al [17] found in a crossover
study that patients who went back in the second phase
from lispro to standard soluble insulin showed a decline
in satisfaction on the retrospective measure, indicating
that the DTSQc does not always invoke positive respond-
ing. Moreover the DTSQc was used in a recent waiting list
control trial [23]: although only the DTSQs results were
included in the 2002 BMJ paper [23], the DTSQc was used
pre- and post-intervention in waiting list controls and
showed no change immediately pre-intervention (com-
pared with baseline), but marked changes post-interven-
tion (Speight, personal communication 2003). These
studies suggest that the DTSQc does not simply elicit pos-
itive change responses regardless of treatment circum-
stances, but does genuinely reflect a response to
improvements in treatment borne out by experience.
The DTSQc is designed specifically for use in a treatment
intervention situation to allow explicit retrospective com-
parison between treatments. In studies of treatment inter-
ventions, where patients' baseline scores show no ceiling
effect, researchers will not necessarily need to use the
DTSQc at endpoint. Since the DTSQc is a measure of com-
parative satisfaction, a measure of absolute Satisfaction
should always be used at baseline using the original Status
version of the DTSQ, to enable researchers to put the find-
ings of the Change measure into context, i.e. the DTSQc
Table 11: Comparison of effect sizes for differences between the DTSQc and DTSQsDiff scores
 Study At Ceiling (("AC")/ 
At Floor ("AF")
t (df) D (= Z of difference 
between t for 
DTSQc and t for 
DTSQsDiff)
Z of difference 
between D in the 
AC/Not AC groups 
or in the AF/Not 
AF groups
DTSQc 
Questionnaire
DTSQsDiff 
Questionnaire
Treatment Satisfaction
Type 1 AC 15.64 (95) -2.44 (91) 10.15 3.83****
Not AC 11.97 (97) 3.30 (94) 4.73
Type 2 AC 27.10 (89) 0.39 (83) 11.23 4.05****
Not AC 26.81 (52) 7.37 (50) 5.51
Perceived Hypoglycaemia
Type 1 AF -4.73 (95) 6.65 (91) -7.54 -6.71****
Not AF -3.48 (99) -6.62 (100) 1.94
Type 2 AF -7.37 (114) 4.79 (113) -8.07 -7.47****
Not AF -2.70 (32) -7.40 (29) 2.49
Perceived Hyperglycaemia
Type 1 AF -5.48 (33) 2.85 (33) -5.22 -5.73****
Not AF -2.14 (159) -6.45 (156) 2.88
Type 2 AF -3.15 (27) 2.77 (28) -3.84 -4.08****
Not AF -2.27 (113) -10.32 (116) 1.93
(**** <0.0001)Page 10 of 12
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person was in the first place. Researchers may wish to
include the Status version at endpoint as well (prior to
completion of the Change version), in view of the appar-
ent greater responsiveness of the DTSQsDiff measure in
these studies for those with poorer perceived blood glu-
cose control at baseline (i.e. Not at Floor). This would also
enable them to draw comparisons between their findings
and those from earlier studies using only the DTSQs.
A further possible advantage of retrospective change
measures is that they may correspond more closely to the
kind of reports that patients are most likely to give in rou-
tine clinical practice. Thus research findings based on ret-
rospective change measures are likely to translate more
directly into clinical practice. The one study of insulin lis-
pro that used the DTSQ Change measure was able to show
the substantial increases in patient satisfaction [17] appar-
ent to clinicians in their routine practice, instead of the
more modest, though significant, improvements apparent
with the DTSQ Status [17].
Conclusion
Although the DTSQc measure was introduced to combat
problems resulting from ceiling effects, it was found here
that the measure of treatment satisfaction derived from
the DTSQc questionnaire was more responsive than that
derived from the DTSQsDiff measure, even when scores
were not at ceiling, and so can be recommended as the
method of choice for measuring change in satisfaction
alongside the DTSQs.
Using a status measure, patients' satisfaction with a new
treatment may appear to be no different from their satis-
faction with their old treatment when they already felt sat-
isfied with the previous treatment, and differences
between treatments may be underestimated. This can give
rise to potentially misleading conclusions, as patients
appear not to value a new treatment as highly as in fact
they do. In these insulin glargine studies the change ver-
sion of the DTSQ has shown that it is able to overcome the
effects of baseline ceiling/floor scores on outcomes. It ena-
bles patients to record their experience of change in satis-
faction and perceived blood glucose control more
precisely and thus provides greater validity in determining
the benefits or drawbacks of a new treatment.
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